FDA Accelerates Approval of Jemperli for Certain Rectal Cancer Patients, Potentially Avoiding Chemotherapy and Surgery

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Jemperli (dostarlimab) for adults with stage II or III locally advanced rectal cancer whose tumors are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR). This groundbreaking immunotherapy, supported by research from Memorial Sloan Kettering Cancer Center, offers the possibility of eliminating cancer without traditional treatments like chemotherapy, radiation, or major surgery.